- Copyright © 2014, The American Academy of Pediatrics
The manufacturer of Tamiflu (oseltamivir) is reporting a supply shortage, according to the Food and Drug Administration. Genentech is experiencing temporary delays in manufacturing oseltamivir phosphate oral suspension 6 mg/ML; 60 mL (NDC 00004-0820-09). The shortage is expected only until mid-January, when additional supply is anticipated.
Oseltamivir is available as Tamiflu in 30-mg, 45-mg, and 75-mg capsules and as a powder for oral suspension that is reconstituted to provide a final concentration of 6 mg/mL. For the 6-mg/mL suspension, a 30-mg dose is given with 5mL of oral suspension, a 45-mg dose is given with 7.5 mL oral suspension; a 60-mg dose is given with 10 mL oral suspension, and a 75-mg dose is given with 12.5 mL oral suspension. If the commercially manufactured oral suspension is not available (e.g., during times of a shortage), a suspension can be compounded by retail pharmacies (final concentration also 6 mg/mL), based on instructions on the package label.
Tamiflu remains the antiviral drug of choice for the management of influenza infections. Timely oseltamivir treatment can reduce the risks of complications, including those resulting in hospitalization and death.
For more information about the recommended dosage and schedule of influenza antiviral medications for treatment and chemoprophylaxis for the 2013–2014 influenza season, see table 3 of the AAP Policy Statement, “Recommendations for Prevention and Control of Influenza in Children, 2013–2014,” at http://pediatrics.aappublications.org/content/132/4/e1089.full.pdf+html?sid=326ed339-7a88-40a9-864f-5bf76211e0e7.
Information about alternatives to Tamiflu is available at, http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm.